s
s
Produodopa® Initiation and Management1
Conversion
In a clinical study, the dose conversion from oral medications was completed with 1 outpatient visit2*
Initiation
Treatment initiation can be during “Off” or “On” state†
Instruct patients to rotate the infusion site and use a new infusion set at least every 3 days
Dose Adjustments
Dose adjustments may be necessary during the optimisation period‡
*Oral medications include all levodopa-containing formulations used during waking time of the day as well as COMT inhibitors.
†If treatment is initiated during “Off” state, a loading dose can be administered immediately prior to commencing the hourly infusion to quickly achieve symptomatic control.
‡The dose may be adjusted to reach a clinical response that maximizes the functional “On” time and minimises the number and duration of “Off” episodes and “On” episodes with troublesome dyskinesia.
COMT=catechol-O-methyltransferase.
For full dosing information please refer to the Produodopa® Summary of Product Characteristics available at www.medicines.ie.
Produodopa® Dosing Overview1
CALCULATE
the Levodopa Equivalents (LEs) based on the patient's current oral levodopa intake during awake hours.
Only levodopa-containing medications and COMT inhibitors should be considered.* The LE amount will inform the calculations for your patient's hourly infusion rates.
DETERMINE
the continuous hourly infusion rates: base, high, and low.
The base hourly infusion rate treats the patient with the equivalent amount of levodopa, adjusted for
24-hour delivery. The pump allows for 3 flow rates (base, low, and high) that can be programmed for patient use.
CHOOSE
the loading dose and extra-dose volumes
A loading dose can be administered to quickly achieve symptomatic control if a patient’s treatment is initiated during an “Off” state, or if they’ve disconnected the pump for more than 3 hours.†
An extra dose can be administered during continuous infusion if the patient is experiencing acute “Off” symptoms.
COMT=catechol-O-methyltransferase.
*The concomitant use of Produodopa® with other levodopa-containing medications or with medicinal products that significantly regulate synaptic dopamine levels (such as COMT inhibitors) has not been studied.
†For interruptions longer than 1 hour, a new infusion set (tubing and cannula) should be used and rotated to a different infusion site.
For full dosing information please refer to the Produodopa® Summary of Product Characteristics available at www.medicines.ie.
Produodopa® Dosing Information1
CUSTOMISABLE DOSING
Offers a wide range of dosing, up to 4260 mg levodopa/day
Infusion rates may be adjusted in increments as small as 0.01 mL/hour (~1.7 mg of levodopa/hour)
3 programmable flow rates (low, base, high) and an extra-dose capability
The only LD/CD SC delivery system with a single infusion site and cannula that can remain in place for up to 3 days*
DOSING CONSIDERATIONS
Produodopa® replaces levodopa-containing medications and COMT inhibitors and can be taken alone or, if necessary, with other concurrent medicinal products for PD, based on the judgment of the HCP.
Produodopa® bypasses the gut, so food does not change absorption or exposure of levodopa/carbidopa.
COMT=catechol-O-methyltransferase inhibitor; HCP=healthcare professional; LD/CD=levodopa/carbidopa; PD=Parkinson's disease; SC=subcutaneous.
*Rotate the infusion site and use a new infusion set at least every three days
For full dosing information please refer to the Produodopa® Summary of Product Characteristics available at www.medicines.ie.
The Vyafuser™ Pump:
Designed to Meet the Unique Needs of Patients
The Vyafuser™ pump connects to your patient’s abdomen via a cannula, and can be worn in multiple ways.1,3,4
For full information on the pump please refer to the Produodopa® Healthcare Professionals Pump Instructions for Use, and also the Produodopa® Summary of Product Characteristics available at www.medicines.ie
WHY PRODUODOPA?
CLINICAL PROFILE
SAFETY
INITIATION & CUSTOMISATION
- Produodopa® (foslevodopa/foscarbidopa solution for infusion) Summary of Product Characteristics, available on www.medicines.ie.
- Soileau MJ, et al. Lancet Neurol. 2022; 21:1099–1109 (incl. suppl.).
- Produodopa® Pump Instructions for Use. 2024.
- Produodopa® Healthcare Professionals Pump Instructions for Use. 2024.
IE-PRODD-230027 Date of preparation: August 2024.
